The Human Immunodeficiency Virus type 1 (HIV-1) is the causative agent of Acquired Immunodeficiency Syndrome (AIDS). One of the critical components of the HIV-1 virus is the envelope glycoprotein gp41, which plays a crucial role in the virus’s ability to infect host cells. The recombinant form of this protein, particularly the 16kDa fragment, has been extensively studied for its potential applications in research and therapeutic development.
The gp41 protein is a subunit of the HIV-1 envelope glycoprotein complex, which also includes gp120. Together, these proteins facilitate the virus’s entry into host cells. Gp41 is a type I transmembrane protein with a single membrane-spanning domain . It is responsible for mediating the fusion of the viral membrane with the host cell membrane, a critical step in the viral infection process.
The recombinant form of gp41, specifically the 16kDa fragment, is produced using various expression systems, such as Escherichia coli . This recombinant protein is often used in research to study the mechanisms of HIV-1 entry and to develop potential inhibitors that can block this process. The 16kDa fragment includes key regions of gp41 that are involved in the fusion process, making it a valuable tool for studying the protein’s function and interactions.
Recombinant gp41 proteins, including the 16kDa fragment, are used in various applications: